Back to Archived Journals » Open Access Bioinformatics » Volume 2

Antigenic epitopes prediction and MHC binder of a paralytic insecticidal toxin (ITX-1) of Tegenaria agrestis (hobo spider)

Authors Ingale A

Published 4 August 2010 Volume 2010:2 Pages 97—103

DOI https://doi.org/10.2147/OAB.S11886

Review by Single-blind

Peer reviewer comments 3


AG Ingale

Department of Biotechnology, School of Life Sciences, North Maharashtra University, Jalgaon, India

Abstract: Spider peptide toxins with nanomolar affinities for their receptors are promising pharmacological tools for understanding the physiological role of ion channels and as leads for the development of novel therapeutic agents and strategies for ion channel-related diseases. Paralytic insecticidal toxin (Tegenaria agrestis) involved multiple antigenic components to direct and empower the immune system to protect the host from infection. MHC molecules are cell surface proteins, which take active part in host immune reactions and involvement of MHC class in response to almost all antigens, and it affects specific sites. Predicted MHC binding regions act like red flags for specific antigens and generate an immune response against the parent antigen. So a small fragment of antigen can induce an immune response against whole antigen. This theme is implemented in designing subunit and synthetic peptide vaccines. In this study, we analyzed secondary structure and antigenic determinants, which form antibodies against infection. The method integrates prediction of peptide MHC class binding and solvent accessible regions. Antigenic epitopes of paralytic insecticidal toxin are important antigenic determinants against the various toxic reactions and infections. There are 3 antigenic determinants in sequence. The results show highest pick at position 4–25 (QLMICLVLLPCFFCEPDEICRA) amino acid residue and 34–51 (YKSNVCNGCGDQVAACEA) amino acid residue.

Keywords: antigen prediction, modeling, ITX-1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]